Literature DB >> 10889822

The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study.

B Paule1, J Belot, C Rudant, C Coulombel, C C Abbou.   

Abstract

AIMS: Interleukin 6 (IL-6) is produced by some renal carcinoma cell lines in vitro. This might be biologically important because IL-6 is a cytokine of particular interest, owing to its involvement in the growth of renal cell carcinoma. In this study, the expression of IL-6 protein in tissue samples from primary renal cell carcinoma was analysed, and then its clinical importance was examined.
METHODS: The distribution of IL-6 in renal cell carcinoma was examined by means of an immunohistochemical method in 47 untreated primary renal cell carcinoma samples. The search for a significant difference between histological patterns, Furhman's grading system, TNM classification, and IL-6 protein expression was carried out.
RESULTS: Immunohistochemistry demonstrated that IL-6 is expressed in 70% of primary tumours. There was no significant difference in the tumour size and grade between renal cell carcinomas with or without IL-6 expression. However, a relatively large number of high grade tumours expressed IL-6.
CONCLUSION: The importance of IL-6 expression with regard to tumour size/local growth is questionable because IL-6 has been correlated with the development of metastatic disease. These data suggest that the production of IL-6 could exert a growth inhibitory effect on primary renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889822      PMCID: PMC1731193          DOI: 10.1136/jcp.53.5.388

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  Expression of the interleukin 6 receptor in primary renal cell carcinoma.

Authors:  V Costes; J Liautard; M C Picot; M Robert; N Lequeux; J Brochier; P Baldet; J F Rossi
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

2.  Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma.

Authors:  B Paule; D Clerc; C Rudant; C Coulombel; L Bonhomme-Faivre; J Quillard; M Bisson
Journal:  Hum Pathol       Date:  1998-04       Impact factor: 3.466

3.  Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.

Authors:  S Miki; M Iwano; Y Miki; M Yamamoto; B Tang; K Yokokawa; T Sonoda; T Hirano; T Kishimoto
Journal:  FEBS Lett       Date:  1989-07-03       Impact factor: 4.124

4.  Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells.

Authors:  J Lotem; L Sachs
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

5.  Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.

Authors:  L Lagneaux; A Delforge; C Dorval; D Bron; P Stryckmans
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

6.  Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression.

Authors:  C Lu; M F Vickers; R S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Interleukin-6 in renal cell carcinoma.

Authors:  T Tsukamoto; Y Kumamoto; N Miyao; N Masumori; A Takahashi; M Yanase
Journal:  J Urol       Date:  1992-12       Impact factor: 7.450

8.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

9.  Enhanced expression of interleukin-6 in primary human renal cell carcinomas.

Authors:  J Takenawa; Y Kaneko; M Fukumoto; A Fukatsu; T Hirano; H Fukuyama; H Nakayama; J Fujita; O Yoshida
Journal:  J Natl Cancer Inst       Date:  1991-11-20       Impact factor: 13.506

Review 10.  Adult renal epithelial neoplasms.

Authors:  L M Weiss; A B Gelb; L J Medeiros
Journal:  Am J Clin Pathol       Date:  1995-05       Impact factor: 2.493

View more
  11 in total

Review 1.  Thrombocytosis as a prognostic marker in gastrointestinal cancers.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2014-02-15

2.  Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients.

Authors:  Sarfraz Ali; Qiqin Yin-Goen; Timothy V Johnson; Wei Han; Nicole A Johnson; Wayne B Harris; Fray F Marshall; Andrew N Young; Viraj A Master; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2010-11-18

3.  Thrombocytosis of Liver Metastasis from Colorectal Cancer as Predictive Factor.

Authors:  Valéria Jósa; Marcin Krzystanek; Tamás Vass; Tamás Lang; Viktória Juhász; Kamilla Szilágyi; Balázs Tihanyi; László Harsányi; Zoltán Szállási; Ferenc Salamon; Zsolt Baranyai
Journal:  Pathol Oncol Res       Date:  2015-03-13       Impact factor: 3.201

4.  Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.

Authors:  Antonia Digklia; Ioannis A Voutsadakis
Journal:  Obstet Gynecol Sci       Date:  2014-11-20

5.  Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma.

Authors:  Morgan Steele; Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2017-01-15

6.  Prognostic evaluation of resectable colorectal cancer using platelet-associated indicators.

Authors:  Weihua Qian; Xin-Xin Ge; Jing Wu; Fei-Ran Gong; Meng-Yao Wu; Meng-Dan Xu; Lian Lian; Wen-Jie Wang; Wei Li; Min Tao
Journal:  Oncol Lett       Date:  2019-05-21       Impact factor: 2.967

7.  Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma.

Authors:  Takao Kamai; Naohisa Tomosugi; Hideyuki Abe; Kyoko Arai; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2009-08-05       Impact factor: 4.430

8.  Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma.

Authors:  Chih-Jung Chen; Wen-Wei Sung; Yueh-Min Lin; Mu-Kuan Chen; Ching-Hsiao Lee; Huei Lee; Kun-Tu Yeh; Jiunn-Liang Ko
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer.

Authors:  Athina Stravodimou; Ioannis A Voutsadakis
Journal:  Int J Breast Cancer       Date:  2013-06-24

10.  Significance of Interleukin-6 in Papillary Thyroid Carcinoma.

Authors:  Toral P Kobawala; Trupti I Trivedi; Kinjal K Gajjar; Darshita H Patel; Girish H Patel; Nandita R Ghosh
Journal:  J Thyroid Res       Date:  2016-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.